SWOG clinical trial number
SWOG-9135

A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Pancreatic Adenocarcinoma

Closed
Phase
Published
Abbreviated Title
A Phase II Trial of Taxol and Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Pancreatic Adenocarcinoma
Activated
06/01/1992
Closed
01/15/1993

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

2014

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single arm phase II trials

PA Philip;K Chansky;L Rubenstein;M Leblanc;L Seymour;SP Ivy;SR Alberts;PJ Catalano;J Crowley Clinical Cancer Research 20(16):4176-4185;

PMid: PMID24914040 | PMC number: PMC4296727

1997

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study.

RP Whitehead;J Jacobson;TD Brown;SA Taylor;GR Weiss;JS Macdonald Journal of Clinical Oncology 15(6):2414-2419

1993

A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas.

T Brown;C Tangen;T Fleming;J Macdonald ASCO 12:200(#592)

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase